-
Product Insights
NewNet Present Value Model: Vicore Pharma AB’s VP-01
Empower your strategies with our Net Present Value Model: Vicore Pharma AB's VP-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-301 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-301 in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VP-301 in Lymphoma Drug Details: VP-301 is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-301 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-301 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VP-301 in Solid Tumor Drug Details: VP-301 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-301 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-301 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VP-301 in Relapsed Multiple Myeloma Drug Details: VP-301 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-01 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-01 in Pulmonary Arterial Hypertension report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-001 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-001 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VP-001 in Retinitis Pigmentosa (Retinitis) Drug Details: VP-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-20621 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.VP-20621 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details:VP-20621 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DS-2325a in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DS-2325a in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DS-2325a in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)...
-
Sector Analysis
Methanol Industry Outlook in Japan to 2028 – Market Size, Price Trends and Trade Balance
What is covered in the report about the “Japan Methanol Industry”? GlobalData’s report, “Methanol Industry Outlook in Japan to 2028 - Market Size, Price Trends and Trade Balance”, provides up to date in-depth information on Japan’s Methanol industry. The report presents major market trends. The report offers historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data. *Note: This is an on-demand report and will be delivered in 3 working days (excluding weekends)...